Prevalence and factors associated with lipodystrophy in AIDS patients

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 47, Issue 1, 2014, Pages 30-37

  Justina, Lunara Basqueroto Della ^a   Luiz, Magali Chaves ^b   Maurici, Rosemeri ^a   Schuelter Trevisol, Fabiana ^a,c  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^b Centro de Doenças Infecciosas HospitalNereu Ramos   (Brazil)

^c HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

Author keywords

Acquired immune deficiency syndrome; HIV; HIV associated lipodystrophy syndrome; Lipodystrophy; Prevalence

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; ETHNICITY; FEMALE; HEALTH CARE; HUMAN; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; OUTPATIENT; PHYSICAL ACTIVITY; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; SEDENTARY LIFESTYLE; SMOKING; VIRUS LOAD; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84895764371     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0240-2013     Document Type: Article

References (54)

1. Alencar TMD, Nemes MIB, Velloso MA. Transformações da "aids aguda" para a "aids crônica": percepção corporal e intervenções cirúrgicas entre pessoas vivendo com HIV e aids. Cienc Saude Coletiva 2008; 13: 1841-1849.
2. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
4. Louie M, Markowitz M. Goals and milestones during treatment of HIV-1 infection with antirretroviral therapy: a pathogenesis-based perspective. Antiviral Res 2002; 55:15-25.
5. Valente AM, Reis AF, Machado DM, Succi RC, Chacra AR. Metabolic alterations in HIV-associated lipodystrophy syndrome. Arq Bras Endocrinol Metabol 2005; 49:871-881.
6. Batterham MJ, Garsia R, Greenopa PA. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy 'Diet FRS Study'. AIDS 2000; 14:1839-1843.
7. Bedimo RJ. Body-fat abnormalities in patients with HIV: progress and challenges. J Int Assoc Physicians AIDS Care (Chic) 2008; 7:292-305.
8. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39: 395-400.
9. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-598.
10. Carr A, Samaras K, Chisholm D, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.
11. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005; 26:88-93.
12. Alencastro PR, Wolf FH, Schuelter-Trevisol F, Ikeda ML, Brandão ABM, Barcellos NT, et al. Characteristics associated to lipodystrophy syndrome among HIV-infected patients naïve and on antiretroviral treatment. J AIDS Clinic Res 2012; 3:1-9.
13. Diehl LA, Dias JR, Paes AC, Thomazini MC, Garcia LR, Cinagawa E, et al. Prevalência da Lipodistrofia Associada ao HIV em Pacientes Ambulatoriais Brasileiros: Relação com Síndrome Metabólica e Fatores de Risco Cardiovascular. Arq Bras Endrocrinol Metabol 2008; 52: 658-667.
14. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella Jr FJ, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389-1398.
15. Baril JG, Junod P, Leblanc R, Dion H, Therrien R, Laplante F, et al. HIV-associated lipodystrophy syndrome: A review of clinical aspects. Can J Infect Dis Med Microbiol 2005; 16:233-243.
16. Sanches RS, Mill J, Machado AA, Donadi EA, Morais Fernandes AP. Facial lipoatrophy: Appearances Are Not Deceiving. J Assoc Nurses AIDS Care 2009; 20:169-175.
17. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000; 10:546-550.
18. Sjöström M, Ainsworth B, Bauman A, Bull F, Craig C, Sallis J. Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ)-Short and Long Forms; 2005.
19. Heyward VH, Stolarczyk IM. Avaliação da composição corporal aplicada. São Paulo: Manole; 2000.
20. Guedes DP. Composição corporal: princípios, técnicas e aplicações. 2nd ed. Londrina: APEF; 1994.
21. Fernandes Filho J. A prática da avaliação física: testes, medidas e avaliação física em escolares, atletas e academias de ginástica. 2nd ed. Rio de Janeiro: Shape; 2003.
22. World Health Organization (WHO). Physical status: the use and interpretation of anthropometry. Technical Report Series. Geneva: WHO; 1995.
23. Ceccato MG, Bonolo PF, Souza Neto AL, Araújo FS, Freitas MI. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil. Braz J Med Biol Res 2011; 44:1177-1183.
24. Monnerat BZ, Cerutti Junior C, Canicali SC, Motta TR. Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitário Cassiano Antonio de Morais, Vitória, ES, Brazil. Braz J Infect Dis 2008; 12:364-368.
25. Della Justina LB, Schuelter-Trevisol F. Prevalência de lipodistrofia associada ao HIV em estudos brasileiros: uma revisão sistemática da literatura; 2013. [no prelo].
26. Tien PC, Grunfeld C. What is HIV-associated lipodydtrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 2004; 17: 27-32.
27. Soares LR. Perfil antropométrico e distribuição da gordura corpórea relacionados ao risco cardiovascular em adultos vivendo com HIV/AIDS [Dissertation]. [São Paulo (SP)]: Faculdade de Medicina da Universidade de São Paulo; 2010.
28. Carvalho EH, Miranda Filho DB, Ximenes RA, Albuquerque MF, Melo HR, Gelenske T, et al. Prevalence of hyperapolipoprotein B and associations with other cardiovascular risk factors among human immunodeficiency virus-infected patients in Pernambuco, Brazil. Metab Syndr Relat Disord 2010; 8:403-410.
29. Trinca JR, Sprinz E, Lazzaretti RK, Hutz MH, Kuhmmer R, Almeida S, et al. SNPs in the APM1 gene promoter are associated with adiponectin levels in HIV-infected individuals receiving HAART. J Acquir Immune Defic Syndr 2010; 55:299-305.
30. Gasparotto AS, Sprinz E, Lazzaretti RK, Kuhmmer R, Silveira JM, Basso RP, et al. Genetic polymorphisms in estrogen receptors and sexual dimorphism in fat redistribution in HIV-infected patients on HAART. AIDS 2012; 26:19-26.
31. Signorini DJHP, Netto AMSO, Monteiro MCM, Signorini DH, Codeço CT, Bastos FI, et al. Diferenças ultrassonográficas da quantidade de gordura corporal e os antirretrovirais. Rev Assoc Med Bras 2012; 58:197-203.
32. Cabrero E, Griffa L, Burgos A, HIV Body Physical Changes Study Group. Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: Results from a study on patients and physician perceptions. AIDS Patient Care STDS 2010; 24:5-13.
33. Hendrickson SL, Kingsley LA, Ruiz-Pesini E, Poole JC, Jacobson LP, Palella FJ, et al. Mitochondrial DNA halogroups influence lipoatrophy after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51:111-116.
34. Guimarães MMM, Greco DB, Ribeiro-Oliveira Jr A, Penido MG, Machado LJC. Distribuição da gordura corporal e perfis lipídico e glicêmico de pacientes Infectados pelo HIV. Arq Bras Endocrinol Metab 2007; 51:42-51.
35. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
36. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003; 4:293-301.
37. Hughes VA, Roubenoff R, Wood M, Frontera WR, Evans WJ, Singh MAF. Anthropometric assessment of 10-y changes inbody composition in the elderly. Am J Clin Nutr 2004; 80:475-482.
38. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and prevalence of lipodystrophy in a population of HIV-infected african subjects receiving highly active antiretroviral therapy. J Acquir Defic Syndr 2007; 46:451-455.
39. Segatto AF, Freitas Junior IF, Santos VR, Alves KC, Barbosa DA, Portelinha Filho AM, et al. Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy. Rev Soc Bras Med Trop 2011; 44:420-424.
40. Ponte CMM. Distúrbios metabólicos associados à infecção pelo HIV/ Aids: prevalência em pacientes ambulatoriais seguidos em hospital de referência do Estado do Ceará, Brasil [Dissertation]. [Fortaleza (CE)]: Universidade Federal do Ceará; 2010.
41. Aukrust P, Muller F, Svardal A, Ueland T, Berge RK, Froland SS. Disturbed glutathione metabolism and decreased antioxidants levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy-potential immunomodulatory effects of antioxidants. J Infect Dis 2003;188:232-238.
42. Bodasing N, Fox R. HIH-associated lipodystrophy: assessment and management. J Infect 2003; 46:87-93.
43. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 (supp I):141-148.
44. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST, Aids e hepatites virais. Recomendações para a prática de atividades físicas para pessoas vivendo com HIV e Aids. Brasília: Ministério da Saúde; 2012.
45. Lindegaard B, Hansen T, Hvid T, van Hall G, Plomgaard P, Ditlevsen S, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab 2008; 93:3860-3869.
46. Mutimura E, Crowther NJ, Cade TW, Yarasheski KE, Stewart A. Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial. AIDS Res Hum Retroviruses 2008; 24:15-23.
47. Ramírez-Marrero FA, Smith BA, Meléndez-Brau N, Santana-Bagur JL. Physical and leisure activity, body composition, and life satisfaction in HIV-positive Hispanics in Puerto Rico. J Assoc Nurses AIDS Care 2004; 15:68-77.
48. Florindo AA, Latorre MRO, Jaime PC, Segurado AA. Leisure time physical activity prevents accumulation of central fat in HIV/AIDS subjects on highly active antiretroviral therapy. Int J STD AIDS 2007; 18:692-696.
49. Schuelter-Trevisol F, Wolff FH, Alencastro PR, Grigoletti S, Ikeda ML, Brandão AB, et al. Physical Activity: Do patients infected with HIV practice? How much? A systematic review. Curr HIV Res 2012; 10: 487-497.
50. Matsudo S, Araujo T, Matsudo V, Andrade D, Andrade E, Oliveira LC, et al. Questionário internacional de atividade física (IPAQ): Estudo de validade e reprodutibilidade no Brasil. Rev Bras Ativ Fis Saúde 2001; 6:5-18.
51. Ogalha C, Luz E, Sampaio E, Souza R, Zarife A, Neto MG, et al. A randomized, clinical Trial to evaluate the impact of regular physical activity on the quality of life, body morphology and metabolic parameters of patients with AIDS in Salavador, Brazil. J Acquir Immune Defic Syndr 2011; 57 (Suppl III):179-185.
52. Fillipas S, Cicuttini FM, Holland AE, Cherry CL. Physical activity participation and cardiovascular fitness in people living with immunodeficiency virus: a one-year longitudinal study. J AIDS Clinic Res 2013; S9:002.
53. Domingo P, Sambeat MA, Pérez A, Ordoñez J, Rodriguez J, Vázquez G. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Antivir Ther 2003; 8: 223-231.
54. Schuelter-Trevisol F, Alencastro PR, Ribeiro PAB, Wolff FH, Ikeda MLR, Barcellos NT, et al. Association of physical activity with lipodystrophy syndrome in HIV-infected patients. J AIDS Clinic Res 2012; 3:177.